MapLight TherapeuticsMPLT +3.09%14 Market Cap is $1,682.78 Mil as of Jul. 03, 2026. GuruFocus rates MPLT with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,427 Biotechnology companies, MapLight Therapeutics ranks better than 85% on this metric.
MapLight Therapeutics's quarterly market cap
increased
from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($773.28 Mil) and
increased
from Dec. 2025 ($773.28 Mil) to Mar. 2026 ($919.10 Mil).
MapLight Therapeutics's annual market cap
stayed the same
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then
increased
from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($773.28 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MapLight Therapeutics's Enterprise Value for Today is $1,377.35 Mil.
MapLight Therapeutics (NAS:MPLT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MapLight Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MapLight Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MapLight Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where MapLight Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
MapLight Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MapLight Therapeutics (MPLT) has a Market Cap of $1,682.78 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MapLight Therapeutics and its competitors. According to the industry distribution chart, MapLight Therapeutics ranks #214 out of 1427 companies in the Biotechnology industry, placing it in the top 15%.
Is MapLight Therapeutics' Market Cap too high?
MapLight Therapeutics' current Market Cap is $1,682.78 Mil. The Biotechnology industry median Market Cap is 119.04. MapLight Therapeutics' value of $1,682.78 Mil is 1313.6% above this industry median. Based on the distribution chart, MapLight Therapeutics ranks #214 out of 1427 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MapLight Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does MapLight Therapeutics' Market Cap compare to COAG and CAPR?
According to the Biotechnology industry distribution chart, MapLight Therapeutics ranks #214 out of 1427 companies for Market Cap. This places MapLight Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.04. MapLight Therapeutics' value of $1,682.78 Mil is 1313.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MapLight Therapeutics's current Market Cap of $1,682.78 Mil is 1313.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MapLight Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MapLight Therapeutics's current Market Cap is $1,682.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MapLight Therapeutics stock overvalued right now?
MapLight Therapeutics (MPLT) has a current Market Cap of $1,682.78 Mil. The current Market Cap is $1,682.78 Mil and 1313.6% above the Biotechnology industry median of 119.04. MapLight Therapeutics' overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MapLight Therapeutics (MPLT), the current Market Cap is $1,682.78 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
14GF Score
Get the complete analysis for MPLT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MPLT has been successfully added to your 
